1. Home
  2. LSF vs NEUP Comparison

LSF vs NEUP Comparison

Compare LSF & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Laird Superfood Inc.

LSF

Laird Superfood Inc.

N/A

Current Price

$3.11

Market Cap

27.3M

ML Signal

N/A

NEUP

Neuphoria Therapeutics Inc.

N/A

Current Price

$5.25

Market Cap

23.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
LSF
NEUP
Founded
2015
1996
Country
United States
United States
Employees
N/A
8
Industry
Packaged Foods
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
27.3M
23.8M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
LSF
NEUP
Price
$3.11
$5.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$6.00
$21.00
AVG Volume (30 Days)
35.5K
41.5K
Earning Date
05-06-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
75.28
N/A
EPS
N/A
N/A
Revenue
$49,889,286.00
N/A
Revenue This Year
$90.82
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
15.23
N/A
52 Week Low
$1.96
$3.65
52 Week High
$7.94
$21.31

Technical Indicators

Market Signals
Indicator
LSF
NEUP
Relative Strength Index (RSI) 64.13 68.35
Support Level $2.41 $3.85
Resistance Level $3.60 $8.86
Average True Range (ATR) 0.23 0.21
MACD 0.05 0.04
Stochastic Oscillator 78.85 96.55

Price Performance

Historical Comparison
LSF
NEUP

About LSF Laird Superfood Inc.

Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: